Cíftçíoglu N, Miller-Hjelle M A, Hjelle J T, Kajander E O
Department of Biochemistry, University of Kuopio, FIN-70211, Kuopio, Finland.
Antimicrob Agents Chemother. 2002 Jul;46(7):2077-86. doi: 10.1128/AAC.46.7.2077-2086.2002.
Compounds from 16 classes of antimicrobial drugs were tested for their abilities to inhibit the in vitro multiplication of nanobacteria (NB), a newly discovered infectious agent found in human kidney stones and kidney cyst fluids from patients with polycystic kidney disease (PKD). Because NB form surface calcifications at physiologic levels of calcium and phosphate, they have been hypothesized to mediate the formation of tissue calcifications. We describe a modified microdilution inhibitory test that accommodates the unique growth conditions and long multiplication times of NB. This modified microdilution method included inoculation of 96-well plates and determination of inhibition by periodic measurement of the absorbance for 14 days in cell culture medium under cell culture conditions. Bactericidal or bacteriostatic drug effects were distinguished by subsequent subculture in drug-free media and monitoring for increasing absorbance. NB isolated from fetal bovine serum (FBS) were inhibited by tetracycline HCl, nitrofurantoin, trimethoprim, trimethoprim-sulfamethoxazole, and ampicillin at levels achievable in serum and urine; all drugs except ampicillin were cidal. Tetracycline also inhibited multiplication of isolates of NB from human kidney stones and kidney cyst fluids from patients with PKD. The other antibiotics tested against FBS-derived NB either had no effect or exhibited an inhibitory concentration above clinically achievable levels; the aminoglycosides and vancomycin were bacteriostatic. Antibiotic-induced morphological changes to NB were observed by electron microscopy. Bisphosphonates, aminocaproic acid, potassium citrate-citric acid solutions, and 5-fluorouracil also inhibited the multiplication of NB in a cidal manner. Insights into the nature of NB, the action(s) of these drugs, and the role of NB in calcifying diseases may be gained by exploiting this in vitro inhibition test system.
对16类抗菌药物的化合物进行了测试,以检测它们抑制纳米细菌(NB)体外增殖的能力。纳米细菌是一种新发现的感染因子,存在于多囊肾病(PKD)患者的肾结石和肾囊肿液中。由于纳米细菌在生理水平的钙和磷酸盐条件下形成表面钙化,因此推测它们介导组织钙化的形成。我们描述了一种改良的微量稀释抑制试验,该试验适应了纳米细菌独特的生长条件和较长的增殖时间。这种改良的微量稀释方法包括接种96孔板,并在细胞培养条件下于细胞培养基中定期测量吸光度,持续14天以确定抑制作用。通过随后在无药物培养基中传代培养并监测吸光度的增加来区分杀菌或抑菌药物作用。从胎牛血清(FBS)中分离出的纳米细菌受到盐酸四环素、呋喃妥因、甲氧苄啶、甲氧苄啶-磺胺甲恶唑和氨苄西林的抑制,这些药物在血清和尿液中可达到的浓度水平即可发挥作用;除氨苄西林外,所有药物均具有杀菌作用。四环素还抑制了从PKD患者的肾结石和肾囊肿液中分离出的纳米细菌的增殖。针对FBS来源的纳米细菌测试的其他抗生素要么没有效果,要么表现出高于临床可达到水平的抑制浓度;氨基糖苷类和万古霉素具有抑菌作用。通过电子显微镜观察到抗生素诱导的纳米细菌形态变化。双膦酸盐、氨基己酸、柠檬酸钾-柠檬酸溶液和5-氟尿嘧啶也以杀菌方式抑制纳米细菌的增殖。通过利用这种体外抑制试验系统,可能会深入了解纳米细菌的性质、这些药物的作用以及纳米细菌在钙化疾病中的作用。